Tuesday, July 1, 2025 7/1/2025

ANTIFIBROTIC THERAPY FOR CHRONIC KIDNEY DISEASE

Award Number: R44DK085841
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2012
PERIOD OF PERFORMANCE END DATE: 07/31/2014

Group Awards By:

View Award Description

ANTIFIBROTIC THERAPY FOR CHRONIC KIDNEY DISEASE - DESCRIPTION (provided by applicant): Chronic kidney disease (CKD) remains an unsolved challenge for the nephrologist, as it almost inevitably leads to end-stage renal failure, a life-threatening condition that necessitates renal replacement therapy. Few, if any, of the currently practiced therapeutic strategies oppose the molecular and cellular program of fibrosis that drives renal disease. There is now mounting evidence that certain receptor tyrosine kinases including platelet derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) are promising targets for development of anti-fibrotic strategies. Under the aegis of the SBIR Phase I program and harnessing a drug discovery engine comprising molecular modeling, rational drug design, medicinal chemistry and in vitro biology, Angion Biomedica has synthesized a highly water soluble, orally bioavailable, small molecule PDGFR+KDR inhibitor, ANG3070. Critical and highly compelling data indicate that ANG3070 is therapeutic in experimental CKD, reducing microalbuminuria and urine TGF21, decreasing renal interstitial collagen accumulation and other markers of renal fibrosis and preserving renal parenchymal microarchitecture. The goal of this proposed milestone driven SBIR Phase II translational research program is to conduct the comprehensive gamut of Investigational New Drug (IND)-enabling studies required to advance our novel, orally bioavailable, small molecule therapeutics to clinical trials in CKD, one of the largest markets of unmet clinical need.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2013 ( Subtotal = $1,062,009 )
2013	2013	ANGION BIOMEDICA CORPORATION	350 COMMUNITY DRIVE	MANHASSET	NY	11030	NASSAU	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	3	8/22/2013	NON-COMPETING CONTINUATION	$1,002,967
2013	2012	ANGION BIOMEDICA CORPORATION	350 COMMUNITY DRIVE	MANHASSET	NY	11030	NASSAU	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	8/1/2013	COMPETING CONTINUATION	$59,042
														Subtotal = $1,062,009

Issue Date FY: 2012 ( Subtotal = $843,452 )
2012	2012	ANGION BIOMEDICA CORPORATION	350 COMMUNITY DRIVE	MANHASSET	NY	11030	NASSAU	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	7/26/2012	COMPETING CONTINUATION	$843,452
2012	2012	ANGION BIOMEDICA CORPORATION	350 COMMUNITY DRIVE	MANHASSET	NY	11030	NASSAU	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	2	8/6/2012	COMPETING CONTINUATION	$0
														Subtotal = $843,452

Grand Total All Awards = $1,905,461

Top

All Categories

About

Search

Reports

Data Submission

Award Information

ANTIFIBROTIC THERAPY FOR CHRONIC KIDNEY DISEASE

Award Number: R44DK085841

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2012

PERIOD OF PERFORMANCE END DATE: 07/31/2014

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer